iBio's GAAP loss for 9 months of fiscal year 2022 was $33.25 million, up 42.5% from $23.327 million in the prior year. Revenue increased 23.5% to $2.322 million from $1.88 million a year earlier.
iBio's GAAP loss for 9 months of fiscal year 2022 was $33.25 million, up 42.5% from $23.327 million in the prior year. Revenue increased 23.5% to $2.322 million from $1.88 million a year earlier. 
ir.ibioinc.com
English (US) 